Edition:
United Kingdom

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

9.68USD
17 Dec 2018
Change (% chg)

-- (--)
Prev Close
$9.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
191,954
52-wk High
$20.65
52-wk Low
$8.55

Chart for

About

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab... (more)

Overall

Beta: --
Market Cap(Mil.): $695.75
Shares Outstanding(Mil.): 51.35
Dividend: --
Yield (%): --

Financials

  CHRS.OQ Industry Sector
P/E (TTM): -- 69.72 34.40
EPS (TTM): -2.70 -- --
ROI: -86.92 9.00 14.96
ROE: -- 10.14 16.53

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.

08 Nov 2018

Coherus prices biosimilar to Amgen's Neulasta at 33 pct discount

Nov 8 Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.

08 Nov 2018

Earnings vs. Estimates